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Abstract The stimulation of platelets by low doses of collagen
induces extracellular signal-regulated kinase 2 (ERK2) activa-
tion. In this report, we demonstrate that collagen-induced ERK2
activation depends on thromboxane A2 (TXA2) formation and
ADP release. The collagen-induced ERK2 activation was inhib-
ited by indomethacin (88%) and by AR-C69931MX (70%), a
speci¢c antagonist of P2Y12, a Gi-coupled ADP receptor. AR-
C69931MX (10 WM) inhibition was overcome by epinephrine
(1 WM), an agonist of the Gi-coupled K2A-adrenergic receptor,
suggesting that the Gi-coupled receptor was necessary for ERK2
activation by collagen. By contrast, MRS 2179 (10 WM), a
speci¢c antagonist of P2Y1, a Gq-coupled ADP receptor, did
not a¡ect collagen-induced ERK2 activation. Little or no ERK2
activation was observed with ADP alone (10 WM). By contrast,
U46619 (10 WM), a stable analog of TXA2, induced ERK2
activation in an ADP-dependent manner, via the P2Y12 recep-
tor. These results suggest that the Gi-dependent signaling path-
way, stimulated by ADP or epinephrine, was not the only path-
way required for ERK2 activation by collagen. Costimulation of
the speci¢c G12=13-coupled TXA2 receptor with a low dose of
U46619 (10 nM) and of Gi- and Gq-coupled ADP receptor (10
WM) induced very low levels of ERK2 activation, similar to
those observed with ADP alone, suggesting that G12=13 is not
involved or not su⁄cient to induce the additional pathway nec-
essary for ERK2 activation. The Gq-coupled TXA2 receptor
was required for ERK2 activation by U46619 (10 WM) and
low doses of collagen, clearly showing that a coordinated path-
way through both Gq from TXA2 and Gi from ADP was nec-
essary for ERK2 activation. Finally, we demonstrate that ERK2
activation is involved in collagen-induced aggregation and secre-
tion.
= 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Collagen is the most thrombogenic component of the sub-
endothelial layer following vascular injury. Collagen supports
platelet adhesion to the subendothelium and subsequently in-
duces aggregation, secretion and procoagulant activity. The
interaction between collagen and platelets is complex and
mediated by several receptors, including integrin K2L1,
GPIV, GPVI, p65 and a TIIICBP type III collagen receptor
[1,2]. The respective roles of these receptors have not been
fully de¢ned. K2L1 and GPVI are now thought to play a
key role in adhesion and activation. K2L1 de¢ciency impairs
collagen-induced platelet adhesion [3]. However, it has been
demonstrated that K2L1 must be activated to acquire a high
a⁄nity for collagen [4]. Signals coupled to GPVI are proposed
to be involved in K2L1 activation. Thus, GPVI appears to
play a central role in activation and in the regulation of ad-
hesion [5]. GPVI is associated with the Q chain of Fc receptors.
GPVI activation by collagen induces FcRQ phosphorylation
and the recruitment of the tyrosine kinase syk, followed by
a cascade of signaling events, including the activation of PI3-
kinase and PLCQ2 [6^8]. Subsequent events include the hydro-
lysis of phosphatidylinositol-4,5 bisphosphate, and the pro-
duction of diacyglycerol and inositol-1,4,5 trisphosphate,
which increases the cytosolic calcium concentration and acti-
vates protein kinase C (PKC) [9,10]. Autocrine agonists, such
as adenosine diphosphate (ADP) and thromboxane A2
(TXA2), have been reported to be involved in platelet secre-
tion and aggregation induced by low concentrations of colla-
gen [11]. ADP triggers changes in the a⁄nity of K2L1 for
collagen [12]. The e¡ects of ADP on platelets are mediated
by two purinergic receptors coupled to G proteins. The P2Y1
receptor coupled to Gq initiates platelet shape change by mo-
bilizing calcium (Ca2þ) [13]. The recently cloned Gi-coupled
P2Y12 receptor, which mediates adenylyl cyclase inhibition, is
essential for full aggregation. The other mediator, TXA2, sig-
nals through G12=13 and Gq-coupled receptors [14]. The
G12=13-signaling pathway induces platelet shape change, in-
volving Rho/Rho kinase-mediated phosphorylation of the my-
osin light chain [15] whereas Gq-mediated phospholipase CL
activation appears to play a central role in platelet aggrega-
tion and secretion.
Collagen induces mitogen-activated protein kinase (MAPK)
activation [16]. Platelet MAPKs include the extracellular sig-
nal-regulated kinase (ERKs), the c-Jun N-terminal kinase
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(JNK) and p38 MAPK [17^19]. ERKs are activated by vari-
ous agonists, including thrombin, collagen, and TXA2 [17].
The induction of ERK activation by thrombin is dependent
on PKC and the tyrosine/threonine kinase MEK1/2, which
phosphorylates ERK1/2 directly [20] but independently of
the serine/threonine kinases Raf-1 and B-Raf [21]. We have
shown that, in conditions of thrombin-induced platelet aggre-
gation, ERK2 is downregulated by the engagement of KIIbL3
integrin and is selectively dephosphorylated at the threo-
nine183 position, via an unidenti¢ed serine/threonine phospha-
tase [22]. However, the role of ERK2 in platelets is beginning
to be unraveled. The ERK cascade regulates store-mediated
Ca2þ entry in platelets [23]. GPIb-IX mediates the activation
of integrin KIIbL3 via a MAPK pathway [24,25]. In transgenic
mice overexpressing the human P2X1 ion channel, preinjec-
tion of the inhibitor of ERK2 activation protects against
thrombosis [26].
In this study, we investigated the roles of ADP and TXA2
in collagen-induced ERK2 activation. We showed that ERK2
activation induced by low doses of collagen (10 Wg/ml) is de-
pendent on the P2Y12 receptor, via ADP and TXA2 synthe-
sis. Moreover, whereas the analog of TXA2, U46619, induced
ERK2 activation via ADP, ADP alone failed to induce ERK2
activation, suggesting that a concomitant pathway connecting
ADP and TXA2 is necessary. We provide evidence that G12=13
coupled to the TXA2 receptor plays a minor role in ERK2
activation induced by collagen whereas Gq coupled to the
TXA2 receptor are involved in this concomitant pathway.
Overall, our data show that the ERK2 activation required
for collagen-induced aggregation and secretion is dependent
on collagen receptors (GPVI and K2L1), the Gi-coupled
P2Y12 receptor and the Gq-coupled TXA2 receptor.
2. Materials and methods
2.1. Reagents
Type I collagen from fetal bovine skin was obtained from Chem-
icon International (Temecula, CA, USA). Convulxin (Cvx) was gen-
erously provided by Dr. M. Jandrot Perrus (Paris, France). The
synthetic peptide Arg-Gly-Asp-Ser (RGDS), (K,L-methylene) triphos-
phate 5P-triphosphate (K,L-MeATP), leupeptin, aprotinin, dimethyl-
sulfoxide, apyrase and epinephrine were purchased from Sigma (St.
Louis, MO, USA). Indomethacin and SQ29548 (5-heptenoic acid,
7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2-2-1]-
hept-2-yl]-,[1S-[1K,2K(Z), 3K, 4K]) were obtained from Cayman Chem-
ical Company (Ann Arbor, MI, USA). U46619 (9,11-dideoxy-9K,11K-
methanoepoxyprostaglandin F2K), Y-27632 and stearic acid-
MPKKKPTPIQLNP (Ste-MKPPPPTPIQLNP) were obtained from
Calbiochem (Meudon, France). 5-Hydroxy[side-chain-2-14C]trypta-
mine creatine sulfate (1.85^2.29 GBq mmol) was obtained from Amer-
sham (Buckinghamshire, England). AR-C69931MX and MRS 2179
were generously provided by Dr. B. Humphries (Astra Zeneca, UK)
and Dr. C. Gachet (INSERM 311, Strasbourg, France). Fibrinogen
was obtained from Kordia (Leiden, The Netherlands). The anti-K2L1
integrin monoclonal antibody 6F1 was generously provided by Dr.
Barry S. Coller (New York, USA). The anti-GPVI monoclonal anti-
body 9O12.2 Fab fragments were generously provided by Dr. C.
Lecut (Paris, France). Mouse monoclonal antibody directed against
the phosphorylated form of ERKS (ERKS-P) was obtained from Up-
state Biotechnology (Lake Placid, NY, USA). Polyclonal antibody
directed against the phosphorylated form of p38 MAPK was pur-
chased from Promega (Madison, WI, USA). Peroxidase-conjugated
a⁄nity-pure donkey anti-rabbit IgG was obtained from Jackson Im-
munoresearch Laboratories (West Grove, DA, USA).
2.2. Isolation of platelets
Venous blood was collected from healthy donors free of medication
for at least two weeks prior to blood collection. Conventional in-
formed consent was obtained from all donors, in accordance with
the guidelines of the committee of the French Blood Transfusion
Agency (l’Etablissement FrancTaise de Transfusion Sanguine). Platelet-
rich plasma (PRP) was obtained by centrifugation of whole blood at
120Ug for 15 min at 20‡C, and platelets were isolated by di¡erential
centrifugation once, in citrate bu¡er, pH 6, supplemented with 1034
mM prostaglandin E1, 0.1 U/ml of the ADP scavenger apyrase (aden-
osine-5P-triphosphate diphosphohydrolase), 140 mM NaCl, 5 mM
KCl, 12 mM trisodium citrate, 10 mM glucose, 12.5 mM saccharose
and then again in the same bu¡er but without prostaglandin E1 and
apyrase. The platelet pellet was resuspended in 10 mM HEPES, pH
7.4, 140 mM NaCl, 3 mM KCl, 5 mM NaHCO3, 0.5 mM MgCl and
10 mM glucose. Cell concentration was adjusted to 5U108/ml.
2.3. Platelet aggregation
Platelet aggregation (0.4 ml samples) was assessed in a Chronolog
dual-beam aggregometer with constant stirring (1200 rpm) at 37‡C.
Fibrinogen (0.25 mg/ml) was added to samples in the aggregometer
prior to the addition of methyl-thio-ADP (MeSADP, 10 WM). The
platelets were incubated with various inhibitors, without stirring, at
37‡C, for various times before adding agonists (collagen (10^15 Wg/
ml), MeSADP (10 WM), U46619 (10 nM^10 WM), epinephrine (1 WM),
Cvx 1 nM). Aggregation was measured and expressed as a percent
change in light transmission, with the value for the blank sample
(bu¡er without platelets) set at 100%.
2.4. Platelet secretion
PRP was incubated with [14C]5-HT (0.5 WCi/10 ml PRP) for 30 min
at 37‡C. Platelets were then isolated as described below. [14C]5-HT
secretion was measured in conditions of platelet aggregation. After
2 min of incubation, we added ice-cold EDTA. The samples were
centrifuged for 3 min and the supernatant was removed for liquid
scintillation counting.
2.5. Thromboxane B2 (TXB2) measurement
Washed human platelets (400 Wl, 5U108/ml) were stimulated by
incubation in an aggregometer with or without collagen (10 Wg/ml)
in the presence or absence of other reagents (AR-C69931MX (10 WM),
MRS 2179 (10 WM)) at 37‡C, with stirring. The reaction was stopped
after 2 min of collagen activation, by quickly adding in ice-cold
EDTA (10 mM). The samples were centrifuged at 3000Ug for
1 min. TXB2, the stable metabolite of TXA2, was quanti¢ed by EIA
as previously described [27].
2.6. Immunoblotting
Samples were subjected to immunoblotting as previously described
[18]. Brie£y, platelets were lysed in sodium dodecyl sulfate (SDS)
denaturing bu¡er (100 mM NaCl, 50 mM Tris, 50 mM NaF, 5 mM
EDTA, 40 mM L-glycerophosphate, 100 WM phenylarsine oxide, 1%
SDS, 5 Wg/ml leupeptin, 10 Wg/ml aprotinin, pH 7.4) and heated at
95‡C for 5 min. Proteins were subjected to SDS^polyacrylamide gel
electrophoresis (PAGE) in 12% or 8% acrylamide gels and transferred
to nitrocellulose ¢lters by semi-dry transfer (Enportech, Natrich, MA,
USA). Filters were then incubated overnight at 4‡C with the poly-
clonal primary antibody against ERK-P (1/10 000) and reprobed for
1 h at room temperature with antibodies against ERKs (1/20 000). The
membranes were washed ¢ve times in phosphate-bu¡ered saline with-
out milk and incubated with peroxidase-conjugated rabbit anti-mouse
(1/20 000) or peroxidase-conjugated donkey anti-rabbit (1/20 000) anti-
body for 45 min at room temperature. Immunoreactive bands were
visualized with enhanced chemiluminescence detection reagents
(Pierce).
2.7. Statistics
Results are expressed as meansXS.E.M. for at least three indepen-
dent experiments. Statistical signi¢cance was assessed with Student’s
t-test for paired comparisons.
3. Results
3.1. Collagen-induced ERK2 activation requires K2L1 integrin
and GpVI
3.1.1. Collagen induces ERK2 activation. We ¢rst deter-
mined the conditions required for collagen-induced ERK2
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activation, by incubating platelets with various concentrations
of collagen (0^10 Wg/ml) for 2 min, with stirring. In resting
platelets, ERK2 was not phosphorylated. Phosphorylated
ERK2 (ERK2-P) was detected in the presence of low concen-
trations of collagen (0.2^1 Wg/ml) and ERK phosphorylation
increased signi¢cantly with increasing collagen concentration
(2.5^10 Wg/ml) (Fig. 1A). In parallel, we investigated the pat-
tern of ERK2 activation over time upon treatment with 10 Wg/
ml collagen, with stirring. ERK2-P was not detected in resting
platelets and platelets stimulated with collagen for 30 s (Fig.
1B). ERK2-P was detected after 60 s of collagen activation,
when there was about 24% platelet aggregation. ERK2-P lev-
els peaked at 120 s and then decreased. Thus, our results
con¢rm that ERK2 is activated in a time- and dose-dependent
manner by collagen.
3.1.2. K2L1 integrin and GpVI are involved in ERK2
activation. We then investigated the role of the collagen re-
ceptor K2L1 integrin by adding a function-blocking monoclo-
nal antibody speci¢c for K2L1 integrin (6F1) in conditions of
collagen-induced ERK2 activation (Fig. 2A). The addition of
6F1 (10 Wg/ml) totally inhibited collagen-induced ERK2 acti-
vation, strongly suggesting that K2L1 integrin is required for
ERK2 activation. Collagen-induced ERK2 phosphorylation
was not inhibited when platelet aggregation was inhibited by
the RGDS peptide, suggesting that KIIbL3 integrin does not
participate in ERK2 activation (results not shown).
As Cvx is a selective GPVI activator, we next investigated
Cvx-induced ERK2 activation in conditions of platelet aggre-
gation. ERK2 was phosphorylated with 1 nM Cvx, indicating
that GPVI is coupled to ERK2 activation (Fig. 2B). In these
conditions, platelet aggregation and ERK2 phosphorylation
were not inhibited by 6F1 (Fig. 2B), suggesting that GPVI
alone is able to induce ERK2 activation. In parallel, we in-
vestigated the GPVI-dependent signaling pathway activated
by collagen. Platelets, pretreated with anti-GPVI monoclonal
antibody 9O12.2 Fab fragments [28], were stimulated with
collagen (15 Wg/ml). 9O12.2 (50 Wg/ml) inhibited collagen-in-
duced ERK2 activation, suggesting strongly that a signaling
pathway induced by GPVI is involved in collagen-induced
ERK2 activation (Fig. 2B). Thus, both GPVI and K2L1 in-
tegrin are required for full ERK2 activation by collagen.
3.2. ADP is necessary for collagen-induced ERK2 activation
3.2.1. ADP-triggered P2Y12 activation is required for col-
lagen-induced ERK2 phosphorylation. As ADP activates mul-
tiple G protein pathways, including the Gq and Gi pathways
for ADP, to induce platelet shape change and platelet aggre-
gation, we investigated the role of this mediator in collagen-
Fig. 1. E¡ect of collagen-induced ERK2 activation. Washed human
platelets were stimulated by incubation for 2 min at 37‡C, with stir-
ring, at various concentrations of collagen (0^10 Wg/ml) (A) or for
various periods of time (0^300 s) with collagen (10 Wg/ml) (B).
ERK2 phosphorylation was analyzed by SDS^PAGE, followed by
Western blotting, using a monoclonal antibody speci¢c for ERK2-P
and a polyclonal antibody recognizing total ERK2. Autolumino-
grams are representative of at least three independent experiments.
Fig. 2. Role of GPVI and K2L1 integrin in ERK2 activation.
Washed human platelets were stimulated by incubation for 2 min at
37‡C, with stirring, with (A,B) collagen (10 Wg/ml) or (B) Cvx
(1 nM) in the presence or absence of an antibody against K2L1 in-
tegrin (6F1) (10 Wg/ml: A,B) or anti-GPVI monoclonal antibody
9O12.2 Fab fragments (50 Wg/ml). ERK2 phosphorylation was ana-
lyzed by SDS^PAGE followed by Western blotting with a monoclo-
nal antibody speci¢c for ERK2-P and a polyclonal antibody recog-
nizing total ERK2. Autoluminograms are representative of at least
three independent experiments.
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induced ERK2 activation. When platelets were preincubated
with apyrase (1 U/ml), ERK2 activation induced by collagen
was partially inhibited (Fig. 3A). We thus investigated the role
of the P2Y12 and P2Y1 receptors in ERK2 activation. We
used two selective antagonists: AR-C69931MX, which is spe-
ci¢c for the P2Y12 receptor, and MRS 2179, which is speci¢c
for the P2Y1 receptor [29]. Strong inhibition of the aggrega-
tion (73%) and secretion (95%) induced by collagen (10 Wg/ml)
was observed after 2 min of incubation with collagen in the
presence of AR-C69931MX (10 WM), whereas platelet aggre-
gation and secretion were only slightly inhibited by the antag-
onist of the P2Y1 receptor, MRS 2179 (10 WM) (Fig. 3B). In
these conditions, collagen-induced ERK2 phosphorylation
(100% in the absence of inhibitor) was signi¢cantly inhibited
by AR-C69931MX, reaching 30X 6%, whereas MRS 2179 had
no signi¢cant e¡ect (130X 32% ERK2 phosphorylation).
Thus, ADP plays a crucial role in collagen-induced aggrega-
tion, secretion and ERK2 activation. Moreover, this activa-
tion of ERK2 is mostly dependent on the Gi-coupled P2Y12
receptor.
At a low dose of collagen (1 Wg/ml), ERK2 phosphorylation
has been reported to be mediated by the P2X1 receptor [30].
In our conditions (10 Wg/ml collagen), the addition of K,L-
MeATP (0.5 WM) had no e¡ect on collagen-induced platelet
aggregation and ERK2 activation, demonstrating that ERK2
activation did not require the P2X1 receptor at this dose of
collagen (10 Wg/ml) (Fig. 3C). By contrast, K,L-MeATP (2 WM)
alone induced weak phosphorylation of ERK2, as previously
described [29], suggesting that the P2X1 receptor was not
desensitized in our conditions (Fig. 3C).
To con¢rm the role of the Gi pathway in collagen-induced
ERK2 activation, we investigated whether epinephrine, the
speci¢c ligand of the Gi-coupled K2A adrenoreceptor, could
overcome the inhibition of ERK2 activation by AR-
C69931MX. In these conditions, in which AR-C69931MX
(10 WM) inhibited both collagen-induced aggregation and
Fig. 3. E¡ect of ADP on collagen-induced ERK2 activation. Plate-
lets were stimulated by incubation with collagen (10 Wg/ml) for
2 min, at 37‡C, with stirring, (A) in the presence or absence of
apyrase (1 U/ml) or (B) AR-C69931MX (10 WM) and MRS 2179
(10 WM). C: K,L-MeATP (0.5 WM) and collagen (10 Wg/ml) were si-
multaneously added to apyrase-untreated platelets for 2 min at
37‡C, with stirring. Aggregation and secretion were measured. In
parallel, ERK2 phosphorylation was analyzed by SDS^PAGE fol-
lowed by Western blotting using a monoclonal antibody speci¢c for
ERK2-P and a polyclonal antibody recognizing total ERK2. Auto-
luminograms are representative of at least three independent experi-
ments.
Fig. 4. E¡ect of epinephrine on AR-C69931MX-induced inhibition
of ERK2 activation. A: Platelets were stimulated by incubation
for 2 min, at 37‡C, with collagen (15 Wg/ml), with stirring, in the
presence or absence of AR-C69931MX (10 WM), with or without
epinephrine (1 WM). B: In parallel, ERK2 phosphorylation was ana-
lyzed by SDS^PAGE followed by Western blotting using a mono-
clonal antibody speci¢c for ERK2-P and a polyclonal antibody rec-
ognizing total ERK2. Relative activities are indicated below as the
ratio of ERK2-P over total ERK in %. Results are representative of
four independent experiments.
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ERK2 activation, the addition of epinephrine (1 WM) partially
restored aggregation (62%) and ERK2 phosphorylation (72%)
(Fig. 4A,B). By contrast, epinephrine alone (1 WM), in the
absence of collagen, induced only weak ERK2 activation. In
conclusion, these results show that the Gi-dependent pathway
is involved in collagen-induced ERK2 activation.
3.2.2. MeSADP alone is not su⁄cient to induce full ERK2
phosphorylation. By contrast, when platelets were stimulated
with MeSADP (10 WM), little or no ERK2 phosphorylation
was observed depending on the experiment (Fig. 5). In these
conditions, full aggregation (76%) and Caþþ mobilization (re-
sults not shown) were observed, suggesting that the P2Y1
receptor of ADP was functional and not desensitized. These
results indicate that MeSADP alone is not su⁄cient to induce
full ERK2 activation and suggest that a concomitant signaling
pathway, linking the Gi-coupled P2Y12 receptor for ADP and
another pathway, is required for e⁄cient collagen-induced
ERK2 activation.
3.3. TXA2 is required for ERK2 activation
As collagen is known to induce TXA2 formation, we inves-
tigated its role, using indomethacin, an inhibitor of cyclooxy-
genase. At an indomethacin concentration of 5 WM, which
inhibited collagen-induced aggregation (88X 6%) and secre-
tion (95 X 4%) (Fig. 6A), the level of ERK2 phosphorylation
was decreased by 88%, suggesting a major role for TXA2 in
collagen-induced ERK2 activation (Fig. 6A). These results
were con¢rmed using the antagonist of the TXA2 receptor,
SQ29548 (1 WM) (results not shown). Thus, collagen-induced
ERK2 activation is dependent on the Gi-coupled P2Y12 re-
ceptor and on TXA2 e¡ect. In parallel, stimulation by colla-
gen induction resulted in the synthesis of 42 ng TXB2 X 8 ng/
108 platelets, the stable derivative of TXA2 (results not
shown). In the presence of AR-C69931MX, we observed
weak but signi¢cant inhibition of TXB2 synthesis (30.5 X 3
ng/108 platelets; P6 0.01; 27.4% inhibition) whereas MRS
2179 had no e¡ect (43X 4 ng/108 platelets). Thus, only 30%
collagen-induced TXA2 synthesis is dependent on ADP.
We investigated whether the TXA2 receptor was directly
involved in ERK2 activation. U46619 (10 WM) induced
ERK2 activation (Fig. 6B), which was mostly dependent on
the P2Y12 receptor because AR-C69931MX (10 WM) inhib-
ited ERK2-P by 70%. The P2Y1 receptor was not involved
because MRS 2179 had no e¡ect. Moreover, the RGDS pep-
tide did not a¡ect U46619-induced ERK2 activation, suggest-
ing that KIIbL3 engagement is not involved in ERK2 activa-
tion (results not shown). Thus, the TXA2-stimulated pathway
leading to ERK2 phosphorylation is partially dependent on
the Gi-coupled P2Y12 receptor pathway and independent of
the Gq-coupled P2Y1 receptor pathway.
3.4. G12=13 coupled to the TXA2 receptor plays a minor role in
collagen-induced ERK2 activation
TXA2 activates multiple G protein pathways including the
G12=13 and Gq pathways. We investigated whether the G12=13-
coupled TXA2 receptor was involved in the concomitant path-
way necessary for ERK2 activation.
We ¢rst determined the conditions in which U46619 in-
duced only the G12=13 signaling pathway, without stimulating
the Gq pathway. Low concentrations (10 nM) of U46619
induced a shape change as previously described [31], consis-
tent with the activation of G12=13 alone (Fig. 7A). In the
Fig. 5. E¡ect of MeSADP on ERK2 activation. Platelets were
stimulated with collagen (10 Wg/ml) or MeSADP (10 WM). ERK2
phosphorylation was analyzed by SDS^PAGE followed by Western
blotting using a monoclonal antibody speci¢c for ERK2-P and a
polyclonal antibody recognizing total ERK2. Autoluminograms are
representative of at least three independent experiments.
Fig. 6. E¡ect of TXA2 on collagen-induced ERK2 activation. Plate-
lets were stimulated (A) with collagen (15 Wg/ml) for 2 min, with
stirring, in the presence or absence of indomethacin (5 WM) or (B)
with U46619 (10 WM) for 2 min, at 37‡C, with stirring, in the pres-
ence or absence of AR-C69931MX (10 WM) and MRS 2179 (10
WM). Aggregation and secretion were measured. In parallel, ERK2
phosphorylation was analyzed by SDS^PAGE followed by Western
blotting using a monoclonal antibody speci¢c for ERK2-P and a
polyclonal antibody recognizing total ERK2. The quantitative
ERK2-P results obtained by densitometric analysis are representa-
tive of at least three independent experiments.
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presence of U46619 (10 nM), very weak activation of ERK2
was observed, showing that the G12=13-mediated signaling
pathway alone is not su⁄cient to induce full ERK2 activation.
We stimulated platelets with MeSADP (10 WM), U46619 (10
nM) or both. Basal levels of ERK2 activation induced by
U46619 were not signi¢cantly increased by MeSADP (Fig.
7B). Our results suggest that the combination of G12=13
coupled to the TXA2 receptor and Gi and Gq coupled to
ADP receptors is not su⁄cient to induce full ERK2 activa-
tion.
3.5. Gq coupled to the TXA2 receptor is involved in
collagen-induced ERK2 activation
The main signaling pathway dependent on the Gq-coupled
TXA2 receptor involves the activation of PKCs. We previ-
ously showed that ERK2 activation induced by thrombin
is dependent on conventional PKCs [21]. We investigated
the role of PKCs dependent on the Gq-coupled TXA2 re-
ceptor in ERK2 activation. Platelets were incubated with
GF109203X (10 WM), which inhibits PKCs, before activation
with collagen (10 Wg/ml) or U46619 (10 WM). GF109203X
inhibited collagen- and U46619-induced ERK2 activation
(Fig. 8), demonstrating that PKCs are involved in ERK2 ac-
tivation. Thus, the Gq-coupled TXA2 receptor and the Gi-
coupled ADP receptor seem to be required for ERK2 activa-
tion.
3.6. ERK2 activation is required for collagen-induced
aggregation and secretion
Finally, we investigated the role of ERK2 in collagen-in-
duced platelet aggregation and secretion, using a speci¢c pep-
tide derived from the amino terminus of MEK1 that bound
ERK2 [32]. Platelets were ¢rst incubated for 30 min with
various concentrations of the non-toxic permeable peptide
Ste-MPKKKPTPIQLNP (2^10 WM), a competitive inhibitor
of the MEK1/2, before addition of collagen (15 Wg/ml). In
these conditions, Ste-MPKKKPTPIQLNP inhibited platelet
aggregation dose dependently up to 81% at a concentration
of 10 WM (Fig. 9A). In parallel, we evaluated the phosphor-
ylation of ERK2 and p38 MAPK. Ste-MPKKKPTPIQLNP
(2^10 WM) did not a¡ect collagen-induced p38 phosphoryla-
tion, regardless of the concentration used. By contrast, ERK2
phosphorylation was inhibited by 4 WM of Ste-peptide, a con-
centration that inhibited platelet aggregation (Fig. 9B). Fi-
nally, we assessed the e¡ect of Ste-MPKKKPTPIQLNP on
collagen-induced platelet secretion. Total inhibition of secre-
tion (100%) was observed only at a concentration of peptide
(5 WM) that inhibited platelet aggregation by 71% (Fig. 9C).
By contrast, 2 WM of a control peptide, which did not inhibit
ERK2 phosphorylation, had no e¡ect on platelet aggregation
and secretion (112X 15% and 98X21%, respectively, with the
values for collagen alone taken as 100%). Thus our results
strongly suggest that ERK2 activation is involved in colla-
gen-induced platelet aggregation and secretion.
4. Discussion
MAPKs are ubiquitously expressed and their signaling cas-
cade has been shown to participate in many cellular processes,
including di¡erentiation, adhesion, migration, proliferation
and death. Platelets, which express various families of
MAPKs including ERK2, JNK1 and p38 MAPKs, are acti-
vated by stimuli like thrombin and collagen [16^18]. We re-
cently found that, in contrast to what has been observed in
proliferative cells, the ERK2 cascade induced by thrombin is
Fig. 7. Involvement of the G12=13 signaling pathway in ERK2 acti-
vation. A: Platelets were stimulated by incubation with U46619 (10
nM) for 2 min, at 37‡C, with stirring. Platelet shape change was as-
sessed in a Chronolog dual beam aggregometer with constant stir-
ring (1200 rpm) at 37‡C and ERK2 phosphorylation was quanti¢ed
and analyzed. B: The ERK2 phosphorylation induced by U46619
(10 nM) (G12=13) with or without MeSADP (10 WM) (Gi, Gq) was
analyzed. Results are representative of at least four independent ex-
periments.
Fig. 8. Role of PKCs in collagen-induced ERK2 activation. Colla-
gen- and U46619-induced ERK2 phosphorylation were analyzed in
the presence or absence of GF109203X (10 WM). Results are repre-
sentative of at least three independent experiments.
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independent of the serine/threonine kinases Raf-1 and B-Raf,
but dependent on conventional PKCs and calcium [21]. In this
study, we addressed the question of the triggering of the
ERK2 signaling pathway in conditions of platelet aggregation
induced by low doses of collagen. We demonstrated that col-
lagen-dependent ERK2 activation involved two autocrine me-
diators, ADP and TXA2. This activation was dependent on
the Gi-coupled P2Y12 receptor of ADP and was independent
of the Gq-coupled P2Y1 receptor. Moreover, the P2Y12 re-
ceptor for ADP was required for the activation of ERK2
induced by the stable analog of TXA2, U46619. Surprisingly,
ADP alone, in conditions of platelet aggregation, was not
su⁄cient to induce full ERK2 activation. This provides strong
evidence that, in conditions of collagen activation, ERK2
phosphorylation requires the Gi-coupled P2Y12 receptor of
ADP and an additional pathway working in combination
with ADP. The G12=13-coupled TXA2 receptor played a minor
role in collagen-induced ERK2 activation, and is therefore
unlikely to be involved in the concomitant pathway. In con-
trast, the Gq-coupled TXA2 receptor was essential for colla-
gen-induced ERK2 activation. Our data show that a coordi-
nated pathway between the Gi-coupled P2Y12 receptor for
ADP and Gq-coupled TXA2 is required for collagen-induced
ERK2 activation, and therefore for platelet aggregation and
secretion.
Platelets interact with collagen through a variety of recep-
tors, including K2L1 integrin, GPVI, GPIV, and 65 and 85
kDa proteins [1,2]. Two major surface receptors, the integrin
K2L1 and GPVI are involved in this interaction. Cvx, a selec-
tive activator of GPVI [33], induced ERK2 activation. More-
over, both the Fab fragments of an antibody directed against
GPVI and antibody 6F1 directed against K2L1 integrin inhib-
ited collagen-induced ERK2 activation, which is consistent
Fig. 9. Involvement of ERK2 activation in collagen-induced platelet
aggregation and secretion. Platelets were ¢rst treated with Ste-
MPKKKPTPIQLNP (2^10 WM) for 30 min and then stimulated
with collagen (15 Wg/ml). A: Aggregation was measured. B: ERK2
and p38 phosphorylation were analyzed by SDS^PAGE, followed
by Western blotting using a monoclonal antibody speci¢c for
ERK2-P and a polyclonal antibody recognizing total ERK2, p38-P
and total p38. Autoluminograms are representative of at least three
independent experiments. C: Secretion and aggregation were nor-
malized and expressed as a percent with respect to collagen alone
(taken as 100%)XS.E.M.
Fig. 10. Model of collagen-induced ERK2 activation. Platelets
stimulated with collagen via GPVI and K2L1 integrin release ADP
and produce TXA2. Both ADP and TXA2 induce K2L1 activation.
A: K2L1 integrin activation stabilizes GPVI interactions, enhancing
GPVI signaling like ERK2 activation. B: Alternatively, ERK2 acti-
vation may occur downstream of K2L1 integrin as a consequence of
GPVI signaling.
FEBS 27958 29-12-03
S. Roger et al./FEBS Letters 556 (2004) 227^235 233
with a role for K2L1 integrin and GPVI. The link between
GPVI and K2L1 integrin is still unclear. In mice with L1-
null platelets, GPVI, but not K2L1 integrin, has been reported
to be essential for platelet interaction and activation with
collagen [34]. In contrast, in ex vivo thrombus formation dur-
ing the perfusion of whole blood over collagen, these recep-
tors ^ GPVI and K2L1 ^ have complementary functions [35].
K2L1 has been reported to be activated by inside-out signals
from a G-coupled receptor of ADP, with the P2Y12 receptor
playing a predominant role [12]. Moreover, crosstalk between
GPVI and Gi-coupled receptors during collagen-induced
platelet aggregation has been reported [36]. In our model,
K2L1, GPVI and the P2Y12 receptor are required for colla-
gen-induced ERK2 activation. We propose that GPVI is the
primary and the central collagen receptor that activates K2L1
integrin as an inducible high-a⁄nity receptor and induces the
release of ADP and TXA2 formation (both also activate in-
tegrin). Consequently, activation of K2L1 stabilizes GPVI in-
teractions, which enhances GPVI signaling like ERK2 activa-
tion (Fig. 10). We cannot exclude the possibility that ERK2
activation occurs downstream of K2L1 integrin as a conse-
quence of GPVI signaling.
How does the Gi-coupled ADP receptor function in the
activation of ERK2? Gi is known to inhibit adenylate cyclase
and to reduce cAMP levels [37]. PI3 kinase, a candidate sig-
naling intermediate acting via Gi-coupled P2Y12, does not
seem to be involved in collagen-induced ERK2 activation be-
cause selective inhibitors of PI3 kinase did not signi¢cantly
a¡ect collagen-induced ERK2 activation (results not shown).
Activation of the small GTPase Rap1B in human platelets
was recently reported to require a Gi-dependent pathway
[38,39]. Moreover, the activation of Rap1 mediates sustained
MAPK activation via B-Raf activation in proliferative cells
[40]. We have shown that B-Raf is not activated in conditions
of thrombin induction [21], suggesting that B-Raf is not in-
volved in ERK2 activation. However, we cannot exclude the
possibility that collagen-induced ERK2 activation involves B-
Raf activation.
Consistent with the results of a previous study [30], we
observed little or no ERK2 activation with ADP alone, which
resulted in calcium mobilization (results not shown) and full
aggregation, conditions in which the P2Y1 receptor is func-
tional. Our results suggested that an additional pathway, in
combination with that involving the Gi-coupled P2Y12 recep-
tor, was necessary for collagen-induced ERK2 activation.
Conversely, the analog of TXA2, U46619, which induced
ERK2 activation, was partly dependent on the P2Y12 recep-
tor. A pathway dependent on G12=13 and/or the Gq-coupled
TXA2 receptor may be required. Little or no ERK2 activation
was observed in conditions in which only the G12=13-coupled
TXA2 receptor (U46619: 10 nM) was coactivated with Gi-
and Gq-coupled ADP receptors (10 WM), suggesting that
G12=13 was not required or not su⁄cient to induce full
ERK2 activation with ADP. The other G protein, the Gq-
coupled TXA2 receptor, which induces PKC activation, is
involved in platelet secretion [14]. We cannot rule out the
possible involvement of the P2X1 receptor, which has been
reported to induce ERK2 activation in the presence of low
concentrations of collagen (1 Wg/ml) [30]. In our conditions
(10 Wg/ml collagen), desensitization of the P2X1 receptor by
K,L-MeATP did not a¡ect ERK2 activation, suggesting that
higher doses of collagen required the P2Y12 receptor rather
than the P2X1 receptor. Moreover, in this previous study, in
contrast to our study, ERK2 activation was not a¡ected by
TXA2 synthesis and ADP release. Finally, the abolition by
PKC inhibition of the ERK2 activation induced by collagen
and U46619 strongly suggests that the Gq-coupled TXA2 re-
ceptor is a good candidate for the concomitant pathway. In
conditions of collagen induction, a role of PKCs via the acti-
vation of GPVI cannot be completely excluded. Thus, ERK2
activation appears to require the Gq signaling pathway in-
duced by TXA2, involved in the release of mediators such
as ADP, acting through Gi-coupled receptors. Finally, the
fact that the Gq-coupled P2Y1 receptor is not able to induce
ERK2 activation is probably due to the level of the P2Y1
receptor (250 copies) being too low to induce the strong signal
required for ERK2 activation. Alternatively, the signaling
pathways of the Gq-coupled P2Y1 receptor and Gq-coupled
TXA2 receptor may be di¡erent.
The role of ERK2 in collagen-induced secretion and aggre-
gation is still unclear. Collagen-induced dense granule release
was decreased by a P2Y12 receptor antagonist. The Gi path-
way is essential for the ampli¢cation of secretion and aggre-
gation and the participation of ERK2 in these events cannot
be excluded. In cases in which ERK2 activation is inhibited, a
decrease in platelet aggregation and secretion induced by low
doses of agonists such as collagen, von Willebrand factor and
thrombin has been reported [24,41]. In our conditions,
PD98059, the inhibitor of the MAPK pathway, strongly in-
hibited TXA2 synthesis (by 80%; results not shown) but not
arachidonic acid release (results not shown). Our results
con¢rm that PD98059 acts on cyclooxygenase activity, as re-
ported previously [42]. Consistent with inhibition of cyclooxy-
genase dependent-TXA2 production by PD98059, indometha-
cin inhibited collagen-induced ERK2 activation. Another
strategy was used, with a stearated form of the MEK1-derived
peptide inhibitor 1 (Ste-MPKKKPTPIQLNP) [32]. In these
conditions, in which ERK2 was inhibited but p38 was not,
collagen-induced platelet aggregation and secretion were in-
hibited, providing evidence that ERK signaling was involved
in platelet function.
In conclusion, this study reports that a costimulation path-
way involving the Gi-coupled P2Y12 receptor for ADP and
the Gq-coupled TXA2 receptor is required for the induction
of ERK2 activation necessary for platelet secretion and ag-
gregation. Our data show that collagen-induced ERK2 acti-
vation is a complex integrated process involving various spe-
ci¢c G proteins required for full platelet activation.
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